Wang Yikang, Wang Di, Tian Yu, Yao Yilong, Yu Qi
Department of Neurosurgery, Shengjing Hospital of China Medical University, Room 1701, Sanhao Street 36, Shenyang, 110004, China.
Fluids Barriers CNS. 2025 Mar 11;22(1):26. doi: 10.1186/s12987-025-00633-0.
This study aimed to investigate the feasibility, acceptability, and preliminary efficacy of a ventriculosagittal sinus (VSS) shunt in the treatment of hydrocephalus with elevated cerebrospinal fluid (CSF) protein content. In this single-center retrospective analysis, we enrolled 80 patients with hydrocephalus and elevated CSF protein levels. Based on these procedures, primary cohort was divided into two groups using CSF protein (CSFP) for subsequent analysis to determine the relationship between the clinical effect and CSFP. Preoperative and postoperative computer tomography (CT) scans, clinical symptoms, and CSF laboratory test were compared. Clinical records of 80 patients were analyzed; 44 patients received VSS shunt, 30 patients received ventriculoperitoneal (VP) shunt, and 6 patients received ventriculobladder (VB) shunt. The most significant changes in ventricular size in the VSS shunt group were detected on the 7th day postoperatively from the collected imaging data. Six months after shunt surgery, the overall success rate for VSS shunt (35 of 44, 79.5%) was markedly higher than that for VP shunt (12 of 30, 40%) and VB shunt (1 of 6, 16.7%). The VSS shunt has a positive clinical effect in hydrocephalus with abnormal CSF laboratory results (elevated protein levels), which is more significant than the clinical success rate of VP shunt in terms of both symptoms and imaging results. The degree of relief and improvement of imaging and symptoms were unrelated to the CSFP content. There was no significant difference in the efficacy of VSS shunt between the CSFP < 1.0 g/L group and the CSFP > 1.0 g/L group. No intracranial or extracranial complications related to the surgery were noted during follow-up. The VSS shunt should be considered the first-line treatment option in cases of hydrocephalus with elevated CSFP levels. Moreover, VSS shunt can immediately improve symptoms and alleviate hydrocephalus even though the CSFP was elevated.
本研究旨在探讨脑室矢状窦(VSS)分流术治疗脑脊液(CSF)蛋白含量升高的脑积水的可行性、可接受性及初步疗效。在这项单中心回顾性分析中,我们纳入了80例脑积水且CSF蛋白水平升高的患者。基于这些程序,将主要队列根据CSF蛋白(CSFP)分为两组,以便后续分析确定临床疗效与CSFP之间的关系。比较术前和术后的计算机断层扫描(CT)、临床症状及CSF实验室检查结果。分析了80例患者的临床记录;44例患者接受了VSS分流术,30例患者接受了脑室腹腔(VP)分流术,6例患者接受了脑室膀胱(VB)分流术。根据收集的影像数据,VSS分流术组术后第7天脑室大小变化最为显著。分流术后6个月,VSS分流术的总体成功率(44例中的35例,79.5%)明显高于VP分流术(30例中的12例,40%)和VB分流术(6例中的1例,16.7%)。VSS分流术在CSF实验室检查结果异常(蛋白水平升高)的脑积水中具有积极的临床效果,在症状和影像结果方面均比VP分流术的临床成功率更显著。影像和症状的缓解及改善程度与CSFP含量无关。CSFP<1.0 g/L组和CSFP>1.0 g/L组VSS分流术的疗效无显著差异。随访期间未发现与手术相关的颅内或颅外并发症。对于CSFP水平升高的脑积水病例,VSS分流术应被视为一线治疗选择。此外,即使CSFP升高,VSS分流术也能立即改善症状并缓解脑积水。